Articles about 'Shankar Balasubramanian'

10 Cambridge spinouts on putting their research into practice to improve outcomes for cancer patients - and why Cambridge is a great place to do this.    

Many life-saving drugs directly interact with DNA to treat diseases such as cancer, but scientists have struggled to detect how and why they work – until now.

Four University of Cambridge researchers – Professors Shankar Balasubramanian, David Klenerman, Suchitra Sebastian and Jack Thorne – have been recognised by the Breakthrough Prize Foundation for their outstanding scientific achievements. 

British duo Professor Shankar Balasubramanian and Professor David Klenerman have been awarded the Millennium Technology Prize for their development of revolutionary DNA sequencing techniques.

David Klenerman and Shankar Balasubramanian talk about their discovery of a revolutionary DNA sequencing technology – and the global impact that continues to surprise them.

Four-stranded DNA structures – known as G-quadruplexes – have been shown to play a role in certain types of breast cancer for the first time, providing a potential new target for personalised medicine, say scientists at the University of Cambridge.

Distinguished members of the University of Cambridge have been named in the 2017 New Year Honours list, announced today. Professor Ottoline Leyser, Professor Shankar Balasubramanian and Professor John Pyle are among those who have been recognised for their contributions to society.

Researchers have identified the role that a four-stranded version of DNA may play in the role of cancer progression, and suggest that it may be used to develop new targeted cancer therapies.

A rare DNA base, previously thought to be a temporary modification, has been shown to be stable in mammalian DNA, suggesting that it plays a key role in cellular function.

A trawl through a library of more than 50,000 ‘small molecules’ has identified a potential candidate to inhibit the spread of cancer cells throughout the body. Reported today in the journal Nature Communications, the molecule targets a mechanism of tumour development that had previously been considered ‘undruggable’– in other words, extremely difficult, if not impossible, to target with a drug – and could open the door to further promising new candidates.